|
**Overview**: **ANA ENA Combo 18 Antigens Profile****Introduction**: The ANA ENA Combo 18 Antigens Profile is a diagnostic tool designed to screen for autoimmune disorders using serum samples. Associated with conditions like systemic lupus erythematosus and Sjögrena's syndrome, these disorders present with joint pain, fatigue, and severe complications if untreated, particularly in individuals with autoimmune tendencies. Per the 2023 American College of Rheumatology guidelines, the test employs immunology with immunoassay technology, delivering detailed autoantibody identification over 1-2 days with high sensitivity and specificity, making it a valuable tool for autoimmune screening in clinical settings. This diagnostic falls under autoimmune screening and targets individuals with suspected autoimmune disorders, addressing the challenge of accurate autoantibody detection to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: ANA ENA 18 Pfl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by immunology labs, this test advanced autoimmune disorder diagnostics.**Purpose**: The test screens for 22 antigens including ANA to guide autoimmune assessment, assess immune response, and inform treatment and prevention strategies.**Test Parameters**: 1. ANA, 2. Sm, 3. Ro (SSA), 4. La (SSB), 5. dsDNA, 6. U1-snRNP, 7. Scl-70, 8. Jo-1, 9. Centromere, 10. Histone, 11. Ribosomal P, 12. SmD1, 13. PCNA, 14. Ro-52, 15. nRNP/Sm, 16. SS-A/Ro 60, 17. SS-A/Ro 52, 18. SS-B/La, 19. PM-Scl, 20. Mi-2, 21. Ku, 22. Sp-100.**Pretest Condition**: No fasting required; patients should report joint pain, fatigue, or recent autoimmune symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on joint pain, fatigue, prior autoimmune reactions, or family history of autoimmune disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune disorders including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible autoimmune disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in rheumatology or immunology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Anti-dsDNA test, complement levels, or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in cross-reactive conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ACR Guidelines 2023, Journal of Autoimmunity 2024, Immunology 2025. |
